Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $15.8000 (5.47%) ($14.7600 - $15.9300) on Mon. May. 22, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.05% (three month average) | RSI | 45 | Latest Price | $15.8000(5.47%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS declines -5.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) ARKG(18%) XOP(18%) ARKK(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.025% in a week (0% probabilities). VIXM(-11%) UUP(-10%) UNG(-8%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.025% (StdDev 2.05%) | Hourly BBV | 0 () | Intraday Trend | 5.4% | | | |
|
1 - 5 Day Possible Target | $6.52(-58.73%) | Resistance Level | $16.24 | 5 Day Moving Average | $15.16(4.22%) | 10 Day Moving Average | $15.75(0.32%) | 20 Day Moving Average | $16.24(-2.71%) | To recent high | -14.6% | To recent low | 7.2% | Market Cap | $447m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |